Issn Print: 0923-7534
Publication Date: 2018/01/01
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
M H Pollack; A Betof; H Dearden; K Rapazzo; I Valentine; A S Brohl; K K Ancell; G V Long; A M Menzies; Z Eroglu; D B Johnson; A N Shoushtari
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.